Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Rise and shine, everyone, another busy day is on the way. However, this is also shaping up as a beautiful day as well, despite forecasts predicting rising ...

When doses werer increased rapidly in a Phase I study, patients on Roche’s investigational oral GLP-1 receptor agonist experienced nausea, vomiting, constipation, diarrhea, as well as abdominal and ...

Shares in the Swiss pharma giant fell 4.5% in early European trading. The stock has gained 5% year to date, having jumped 7% in July after Roche said the once-daily drug, acquired through its $3 ...

Shares in Roche fell on Thursday after an early-stage obesity pill candidate that carries high market hopes was linked to a high rate of temporary side effects in its initial test phase on humans.

Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes ...

Roche RHHBY presented results of an early-stage study on its experimental obesity drug, CT-996, at the European Association for the Study of Diabetes annual meeting. CT-996 is an investigational, once ...

For the second trading session in less than a week, Roche Holding ( RHHBY -6.02%) stock really took it on the chin Wednesday.

Roche (RHHBY) stock slid 5% Wednesday after Reuters reported that positive data released in July for Roche's obesity pill ...

Roche's experimental weight-loss pill, CT-996, showed promising early-stage trial results, causing shares to rise. However, ...